Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Needham Maintains Buy on ResMed, Raises Price Target to $236

Author: Benzinga Newsdesk | April 26, 2024 06:24am

Needham analyst Mike Matson maintains ResMed (NYSE:RMD) with a Buy and raises the price target from $224 to $236.

Posted In: RMD